HRT Financial LP lifted its position in AtriCure, Inc. (NASDAQ:ATRC – Free Report) by 886.6% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 78,800 shares of the medical device company’s stock after buying an additional 70,813 shares during the period. HRT Financial LP owned about 0.17% of AtriCure worth $3,266,000 as of its most recent SEC filing.
A number of other large investors have also made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in AtriCure by 6.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 20,237 shares of the medical device company’s stock worth $898,000 after purchasing an additional 1,155 shares in the last quarter. Advisors Capital Management LLC increased its holdings in AtriCure by 0.6% during the 4th quarter. Advisors Capital Management LLC now owns 45,679 shares of the medical device company’s stock worth $2,027,000 after purchasing an additional 283 shares in the last quarter. Barclays PLC boosted its stake in shares of AtriCure by 79.5% during the 1st quarter. Barclays PLC now owns 27,325 shares of the medical device company’s stock worth $1,133,000 after buying an additional 12,105 shares during the last quarter. Commerce Bank boosted its stake in shares of AtriCure by 5.6% during the 1st quarter. Commerce Bank now owns 11,357 shares of the medical device company’s stock worth $471,000 after buying an additional 602 shares during the last quarter. Finally, CenterBook Partners LP boosted its stake in shares of AtriCure by 129.4% during the 4th quarter. CenterBook Partners LP now owns 15,800 shares of the medical device company’s stock worth $701,000 after buying an additional 8,913 shares during the last quarter. Institutional investors own 94.30% of the company’s stock.
Analyst Upgrades and Downgrades
A number of research firms have recently commented on ATRC. Stifel Nicolaus increased their price objective on shares of AtriCure from $50.00 to $59.00 in a research note on Wednesday, July 26th. Piper Sandler increased their price objective on shares of AtriCure from $55.00 to $65.00 in a research note on Wednesday, July 26th. Needham & Company LLC increased their price objective on shares of AtriCure from $60.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, July 26th. BTIG Research increased their price objective on shares of AtriCure from $56.00 to $68.00 in a research note on Wednesday, July 26th. Finally, StockNews.com began coverage on shares of AtriCure in a research note on Thursday, August 17th. They issued a “hold” rating for the company. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $66.80.
View Our Latest Stock Analysis on AtriCure
AtriCure Stock Down 1.1 %
Shares of NASDAQ:ATRC opened at $45.23 on Wednesday. The company has a current ratio of 3.33, a quick ratio of 2.56 and a debt-to-equity ratio of 0.12. AtriCure, Inc. has a 52-week low of $32.51 and a 52-week high of $59.61. The company has a 50-day simple moving average of $50.81 and a 200 day simple moving average of $46.25.
AtriCure (NASDAQ:ATRC – Get Free Report) last released its quarterly earnings results on Tuesday, July 25th. The medical device company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.15. The firm had revenue of $100.92 million for the quarter, compared to analysts’ expectations of $97.55 million. AtriCure had a negative net margin of 7.67% and a negative return on equity of 7.11%. The business’s revenue was up 19.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.32) EPS. Research analysts forecast that AtriCure, Inc. will post -0.93 earnings per share for the current fiscal year.
Insider Buying and Selling at AtriCure
In other news, insider Karl S. Dahlquist sold 3,417 shares of the firm’s stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $57.09, for a total transaction of $195,076.53. Following the transaction, the insider now directly owns 32,037 shares of the company’s stock, valued at $1,828,992.33. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Karen Prange sold 713 shares of the firm’s stock in a transaction that occurred on Thursday, June 8th. The shares were sold at an average price of $47.89, for a total transaction of $34,145.57. Following the transaction, the director now directly owns 16,140 shares of the company’s stock, valued at $772,944.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Karl S. Dahlquist sold 3,417 shares of the firm’s stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $57.09, for a total transaction of $195,076.53. Following the completion of the sale, the insider now owns 32,037 shares in the company, valued at approximately $1,828,992.33. The disclosure for this sale can be found here. Insiders own 3.00% of the company’s stock.
About AtriCure
AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation.
Further Reading
Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRC – Free Report).
Receive News & Ratings for AtriCure Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AtriCure and related companies with MarketBeat.com’s FREE daily email newsletter.
Leave a Reply